2-deoxy-D-glucose (2DG) is a promising cancer treatment adjuvant, particularly in the context of cancer immunotherapies due to its indirect immunomodulatory effects via immunogenic tumor cell death [34] and reduced PD-L1 and PD-1 glycosylation and surface expression [38,39,40,41]. The gene discussed is CD274; the disease is neoplasm.